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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
“platelet-rich plasma injections are effective at reducing pain in adults with knee osteoarthritis?” 
 
STUDY DESIGN: A systematic review of two double-blind, randomized controlled trials 
(RCTs) and one single-blind randomized controlled trial published after 2015. All studies were 
published in English.  
 
DATA SOURCES: The two double-blind randomized controlled trials and one single-blind 
randomized controlled trial were found via PubMed. All sources were published in peer-
reviewed journals and were chosen based on their relevance to the clinical question. 
 
OUTCOMES MEASURED: Pain reduction was the outcome measured in all three studies 
using the WOMAC pain scale. In this systematic review, the level of pain was evaluated at 
baseline and 24 weeks (6 months).  
 
RESULTS: In the double-blind RCT conducted by Cole et.al (Am J Sports Med. 
2017;45(2):339-346. doi: 10.1177/0363546516665809), there was reduction in pain with 
platelet-rich plasma injections with a mean change from baseline of 2.89. However, no statistical 
significance was noted in this study. In the single-blind RCT by Lisi et al. (Clin Rehabil. 
2018;32(3):330-339. doi: 10.1177/0269215517724193), reduction of pain was noted with a 
median change from baseline of 4, but no statistical effect was noted. Lastly, in the double-blind 
RCT by in Rahimzadeh et al. (Clin Interv Aging. 2018;13:73-79. doi:10.2147/CIA.S147757), 
there was reduction in pain with a mean change from baseline of 8.6, as well as statistical 
significance with a p-value of <0.001. 
 
CONCLUSION: While clinical reduction was demonstrated by all three studies based on the 
decrease in mean change from baseline, statistical significance was not noted in the studies 
conducted by Cole et al. (Am J Sports Med. 2017;45(2):339-346. doi: 
10.1177/0363546516665809) and Lisi et al. (Clin Rehabil. 2018;32(3):330-339. doi: 
10.1177/0269215517724193). Thus, the results of this review are inconclusive. Future studies 
need to be designed in order to showcase statistical significance with the use of platelet-rich 
plasma injections in reducing pain in those with knee OA.  
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INTRODUCTION 
Osteoarthritis (OA) is one of the most common forms of arthritis in the knee and it occurs 
due to gradual breakdown of articular cartilage, leading to a decrease in defensive space between 
the bone. This results in bone contact, which can cause production of painful bone spurs in the 
affected area. Approximately 27 million Americans suffer from osteoarthritis, with prevalence 
continuing to increase with age. Individuals aged 25 and older have classified with a 13.9% rate 
of OA in at least one joint, with 33.6% of adults over 65 years suffering from OA as well.1 In 
terms of cost, total costs for the treatment of OA in 2013 was approximately $16.5 billion 
dollars, making it the second most expensive health condition treated in U.S hospitals for that 
year.2 Cost is even greater if the patient requires joint replacement surgery. In 2013 alone, OA 
accounted for 25.7 million healthcare visits and 3 million hospital stays, making it the primary 
cause of hospitalizations compared to other forms of arthritis.3 In total, it represented 10% of all 
hospitalizations and 2% of ambulatory appointments.3  
While the pathophysiology of knee OA is not fully understood, it encompasses a variety 
of factors, such as family history, age, obesity, inflammation mediators, joint space and trauma.4 
Symptoms of knee OA vary depending on the mechanism, but pain around the joint space is the 
most common manifestation which can fluctuate in intensity. This pain is most commonly noted 
in the morning and after prolonged sitting or rest. As OA is considered a major cause of pain and 
disability among adults in the US3, physician assistants can play a large role in helping to 
properly diagnose and effectively treat these patients. 
Treatment for OA varies from person to person and depends greatly on its severity and 
disruption to an individual’s activities of daily living. The goal of treatment is to relieve patients 
of pain and improve their functionality, since there is no definitive way to prevent OA from 
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occurring. Some common nonpharmacological regimens for patients presenting with OA include 
exercise, heat and cold applications, weight loss, acupuncture, transcutaneous electrical nerve 
stimulation, and assistive devices.5 Pharmacological treatment includes NSAIDs, duloxetine, 
capsaicin topical cream, opioid analgesics, and intra-articular injections.5 A last resort for 
patients would be the surgical approach, which includes joint lavage, arthroscopic debridement, 
osteotomy, and joint replacement.5 
The treatment options listed above all play a role in reducing symptoms in those with 
knee OA. However, long-term use of some therapies, such as prolonged NSAID and 
corticosteroid use, could result in other sequelae to the individual, such as putting them at risk for 
cardiovascular or gastrointestinal conditions. Since the only definitive cure for OA is surgery, 
often times individuals look for methods that can help alleviate symptoms associated with 
chronic OA. Platelet-rich plasma (PRP) injections may be used an alternative method that is 
minimally invasive and could help reduce pain in these patients. PRP injections are designed to 
help rebuild cartilage, repair torn ligaments, and reduce pain and swelling in hopes that certain 
patients are able to avoid surgery.9 It is thought that by using one’s own platelets, these injections 
could stimulate natural immune repair mechanisms and supply the growth factors necessary to 
build tissue.9 This paper evaluates three randomized controlled trials (RCTs) evaluating the 
efficacy of platelet-rich plasma injections at reducing pain in adults with knee osteoarthritis.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “platelet-rich 
plasma injections are effective at reducing pain in adults with knee osteoarthritis?” 
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METHODS 
 Three randomized controlled trials that investigated platelet-rich plasma injections as an 
intervention for pain reduction in adults with knee OA were chosen for this analysis. Authors 
Cole et al. and Lisi et al. compared platelet-rich plasma injections with intra-articular hyaluronic 
acid injections and Rahimzadeh et al. compared platelet-rich plasma injections with 
prolotherapy. All three studies looked at the efficacy of PRP injections in reducing pain in adults 
suffering with knee OA.  
 Articles were selected based on searches using the keywords “platelet-rich plasma 
injections” and “knee osteoarthritis”. The studies were published in peer reviewed articles and 
presented in the English language. They were searched via PubMed based on their relevance to 
the clinical question and if they included patient oriented outcomes. Inclusion criteria included 
studies that were published after 2015, randomized controlled trials, human species, and in 
English. Exclusion criteria included studies that were published in 2015 or earlier, studies with 
animals, or studies in a different language. The statistics reported and used in this systematic 
review were p-values, mean change from baseline, and standard deviation. Table 1 below 
demonstrates the demographics and characteristics showcased in the studies.  
OUTCOMES MEASURED 
 The primary outcome measured in this selective EBM review was pain reduction in 
adults with knee OA at baseline and 24 weeks follow-up. All three articles used the Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale to assess pain. The 
WOMAC scale is a self-administered questionnaire that can assess an individual’s level of pain 
while completing daily activities, such as walking, climbing stairs, sleeping, resting, and 
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standing. The scores are totaled and calculated on the scale from 0-20, with 0 indicating no pain 
and 20 indicating extreme pain.6-8 
Table 1. Demographics & Characteristics of included studies 
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 anti-coagulation 






 Cole et al. conducted a double-blind, randomized controlled trial comparing the effects of 
platelet rich plasma injections and hyaluronic acid (HA) intra-articular injections in adults with 
knee OA. A total of 111 patients specified for the treatment of knee OA were selected for this 
study and individuals were chosen based on specific inclusion/exclusion criteria as noted in 
Table 1 above.6 The patients chosen were randomized with the use of an electronic 
randomization process into two groups – one group receiving intra-articular PRP and other group 
receiving intra-articular hyaluronic acid.6 After treatment in both groups, patients were informed 
to limit the use of their leg for a minimum of 24 hours and to apply cold compresses as needed 
for discomfort.6 They were recommended to partake in activities requiring only mild exertion, 
followed by a steady return to recreational activities as tolerated.6 Three weekly injections were 
given to these patients and they were evaluated at baseline, treatment weeks 2 and 3, and follow-
up weeks 6, 12, 24, and 52.6 In order to keep consistency among all three studies, this EBM 
review will only focus on patient outcomes at baseline and 24 weeks follow-up. During the 
follow-up period, 11% of patients were lost to follow-up or were unwilling to complete the 
study, so the final study group consisted of 49 patients in the PRP group and 50 patients in the 
hyaluronic acid group.6 
 In this study, the WOMAC pain scale was used as a primary outcome measurement to 
evaluate the effectiveness of both interventions. The statistical data used to measure the 
outcomes before and after treatment were presented as mean values and standard deviation. The 
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level of significance was measured as a p-value <0.05 between both interventions.6 As shown in 
Table 2 below, both interventions showed some improvement in pain when comparing values at 
baseline and 24 weeks follow-up.6 The PRP group showed a decrease in mean values with 7.00  
0.53 before treatment and 4.11  0.56 at 24 weeks, resulting in a mean change from baseline of 
2.89.6 The HA group demonstrated a decrease in mean values of 7.52  0.58 before treatment 
and 5.00  0.50 after treatment, with a mean change from baseline value of 2.52.6 Although 
trends towards improvement of pain is seen slightly greater in the PRP group, there is no 
statistical significance when comparing both interventions (p = 0.93), implicating a small 
treatment effect.6 Furthermore, this study did not discuss compliance, tolerability, or adverse 
effects among patients in this trial.  
Table 2. WOMAC Mean  SD Change in Pain from Baseline and 24 Weeks Follow-Up and 
Statistical Significance (data from Cole et al.6)  
 Before Treatment 
(Mean  SD) 
24 weeks  





PRP Group 7.00  0.5 4.11  0.56 2.89 0.53 
HA Group 7.52  0.58 5.00  0.50 2.52 
 
 Lisi et al. is a single-blind randomized controlled trial comparing the efficacy of platelet-
rich plasma injections and hyaluronic acid injections in patients with knee OA. Fifty-eight 
patients were chosen for this study based on the eligibility criteria listed in Table 1.7 Patients 
were randomized into either group and if they demonstrated bilateral knee OA, both knees were 
treated with the treatment that was assigned to them.7 The groups were given their allocated 
treatments at an outpatient office from the same study staff at four weeks intervals, using a 
superolateral advancement into the suprapatellar pouch. 7 Patients were monitored for 10-15 min 
after the injections to check for adverse reactions and then discharged home with no restrictions, 
as well as being instructed to take pain medications as needed.7 A total of eight patients were 
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excluded from the final analysis due to unspecified reasons, so the final study group for analysis 
consisted of 28 patients for the PRP group and 22 patients in the HA group.7  
 The WOMAC pain scale was one of the measurements utilized to detect the effectiveness 
of both interventions in reducing pain in these patients. Data were analyzed at baseline, 15 days, 
6 months, and 12 months.7 In order to maintain consistency among the studies in this review, 
data collected at baseline and 6 months will be further discussed. Median values were analyzed 
at these intervals, with the level of significance measured as a p-value <0.05.7 According to 
Table 3 below, both treatment groups showed some degree of improvement in pain when 
compared to the baseline values.7 The PRP group showed a decrease in median values with 4 
before treatment and 0 at 6 months, resulting in a median change from baseline of 4.7 The HA 
group demonstrated a decrease in median values of 7 before treatment and 3 after treatment, with 
a median change from baseline value of 4 as well.7 When comparing both intervention groups, 
there was no statistical significance (p = 0.91).7 Researchers of this study stated that there were 
no adverse effects observed in the intervention group or the control group.7 Compliance and 
tolerability were not discussed in this study. 
Table 3. WOMAC Median Change in Pain from Baseline and 6 Month Follow-Up and 
Statistical Significance (data from Lisi et al.7)  
 Before Treatment 
(Median) 






PRP Group 4 0 4 0.91 
HA Group 7 3 4 
 
Rahimzadeh et al. is a double-blind randomized controlled trial comparing the effects of 
platelet-rich plasma injections against prolotherapy (PRL) in those with knee OA. A total of 42 
patients were chosen for this study based on the inclusion/exclusion criteria listed in Table 1.8 
Block randomization was used to assign the patients to either the intervention group or the 
control group.8 Following proper monitoring of patients’ vital signs, samples were produced and 
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7mL of separated plasma was given to patients in the PRP group while 7mL of 25% dextrose 
was given to those in the PRL group.8 Following the administration of both treatments, patients 
were monitored briefly and discharged home if no adverse effects were noted.8 There was no 
comment regarding losses to follow-up noted in this study.  
The WOMAC pain scale was used to monitor the level of pain in these patients and data 
was collected at baseline, 1 month, 2 months, and 6 months later.8 This review analyzed patients’ 
pain levels at baseline and 6 months using the statistical data of mean values and standard 
deviation. Repeated-measures ANOVA was used to calculate the p-values for each specific 
intervention, with the level of significance being measured at p <0.05.8 According to Table 4 
below, both the PRP group and the PRL group showed improvement in pain levels from 
baseline. The PRP group showed a decrease in mean values of 14.8  1.5 at baseline and 6.2  
2.1 at 6 months, which resulted in a mean change from baseline value of 8.6.8 The PRL group 
demonstrated a decrease in values of 14.6  1.4 at baseline and 8  1.6 at 6 months, resulting in a 
mean change of 6.6.8 Each intervention individually showed statistical significance in reduction 
of pain (p = <0.001).8 While it was mentioned that no adverse effects were noted from either 
intervention group, information regarding compliance and tolerance was not discussed.8  
Table 4. WOMAC Mean  SD Change in Pain from Baseline and 6 Month Follow-Up and 
Statistical Significance (data from Rahimzadeh et al.8) 
 Before Treatment 
(Mean  SD) 
6 Months  





PRP Group 14.8  1.5 6.2  2.1 8.6 <0.001 
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DISCUSSION 
 Osteoarthritis can be a chronic, debilitating condition for many individuals suffering with 
it on a daily basis. OA in the knee specifically is responsible for major wear-and-tear of the knee 
joint and the surrounding capsule, making it a substantial burden in activities of daily living.3  
This systematic review looked into the efficacy of platelet-rich plasma injections as an 
intervention to assist with pain reduction in these specific individuals. All three studies evaluated 
a mean change of pain from baseline to 24 weeks follow-up. Cole et al. and Lisi et al. both 
demonstrated some improvement in pain with a mean change from baseline of 2.89 and 4, 
respectively.6,7 However, statistical significance of this specific treatment was not mentioned in 
either study, making it difficult to determine the pure efficacy of PRP injections in reducing pain. 
On the other hand, Rahimzadeh et al. did demonstrate statistical significance in the improvement 
of pain with PRP with a mean change from baseline of 8.6 and p-value <0.001.8 While all three 
studies did reveal clinical improvement in pain with this intervention, it is unclear whether or not 
it is statistically effective in the reduction of pain in those with knee OA. 
 There were various limitations noted among the studies used in this review. In Cole et al., 
authors mention that there was a difference in BMI between the two intervention groups, which 
could have contributed to some discrepancies in data.6 Another limitation was a lack of a sham 
control group in this study, which would have been an appropriate addition in order to further 
evaluate the efficacy of these interventions.6 In Lisi et al., some limitations mentioned were 
small sample size, limited number of injections given, and short follow-up intervals.7 Authors 
stated that in order to accurately measure patient outcomes, further studies should look towards 
making standardized thresholds in terms of number of injections, intervals between injections, 
and local anesthesia.7 Lastly, in Rahimzadeh et al., limitations included lack of a control group 
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receiving placebo, absence of proper evaluation of cartilage and soft tissue surrounding the knee 
joint, and short time allotted for proper patient assessment.8  
   The use of platelet-rich plasma injections was first noted to be valuable in an open-heart 
surgery in 1987 and has since then expanded into in various healthcare settings, such as to assist 
in healing after spinal injuries and help with sports-related injuries.9 There are multiple variations 
of PRP preparations that are commercially available to use in the US.9 Since PRP injections are 
prepared from autologous blood from the patient themselves, there are minimal risks noted in 
terms of disease transmission and immunogenic reactions in those receiving this treatment.9 
However, with any sort of injection, adverse effects such as infection at the site or scar tissue 
formation may be seen in patients. One issue that can arise with the use of these injections is that 
most insurance plans do not provide coverage for cost, so patients pay out-of-pocket with prices 
ranging from $200-$500.9 These factors need to be taken into consideration in deciding whether 
or not PRP injection therapy is the best option for patients suffering with knee OA.   
CONCLUSION 
 Based on the scope of this systematic review, while there was a clinical reduction in pain 
according to the decrease in mean change from baseline with the WOMAC pain scale, statistical 
significance of the specific treatment group was not reported in two of three studies. Thus, the 
results of this review are inconclusive. Further studies should be performed to provide statistical 
analysis of this intervention in regard to its efficacy in pain reduction from baseline. These future 
studies can also aid in determining if platelet-rich plasma injections vary in efficacy compared to 
other conventional treatment options available. Along with increasing sample size and follow-up 
intervals, future studies should take into consideration the level of physical exercise before and 
during follow-up intervals, as this can have an effect on the patient’s outcome. It is also 
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important to closely monitor safety, tolerability, and adverse effects of platelet-rich plasma 
injections long-term. Knee osteoarthritis is a chronic condition that will continue to affect the 
daily functioning of individuals, so thorough randomized controlled trials need to be proposed in 
order to accurately see the possible benefits of platelet-rich plasma injections in reducing pain in 
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